Open AccessIn Vitro Development of Resistance to Human Immunodeficiency Virus Protease Inhibitor GW640385
Author(s) -
Philip Yates,
Richard Hazen,
Marty St. Clair,
Lauren Boone,
Margaret Tisdale,
Robert C. Elston
Publication year - 2006
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.50.3.1092-1095.2006
Subject(s) - protease , protease inhibitor (pharmacology) , in vitro , virology , biology , virus , amino acid , human immunodeficiency virus (hiv) , viral replication , enzyme , biochemistry , viral load , antiretroviral therapy
Development of in vitro resistance to GW640385, a new human immunodeficiency virus type 1 protease inhibitor, was studied. Variants characterized included one with <4-fold resistance and amino acid substitutions Q58E/A71V (protease) and P452K (Gag) and one with >50-fold resistance and amino acid substitutions L10F/G16E/E21K/A28S/M46I/F53L/A71V (protease) and L449F/P453T (Gag). The A28S substitution substantially reduced replication capacity.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom